PharmGen Science Signs Joint Research Agreement with EigenDrug... Developing AI-Based New Drugs for Autoimmune Diseases
[Asia Economy Reporter Lee Gwanju] PharmGen Science announced on the 28th that it has signed a joint research agreement with AI platform-based innovative drug development company EigenDrug to develop new drugs for autoimmune diseases, including inflammatory bowel disease (IBD).
This joint research aims to discover effective substances for autoimmune diseases by utilizing EigenDrug's AI drug development platforms: the drug-target interaction prediction model (EnsDTI), the human liver toxicity prediction model (SSM), and the self-supervised learning drug development model (TriCL). EigenDrug proposes candidate compounds based on AI-derived chemical structures, and PharmGen Science conducts synthesis and efficacy verification of the proposed candidates.
EigenDrug is an AI-based drug development specialized company founded last year by Professor Kim Sun of Seoul National University's Department of Computer Science, a leading scholar in the AI field. Professor Kim is a bioinformatics and AI expert who taught computer information science for over 10 years at Indiana University in the United States, led the national bio big data construction pilot project, and served as president of the Artificial Intelligence Society.
A PharmGen Science official stated, "This joint research was also selected for the AI-utilized new drug development project led by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association," adding, "By integrating EigenDrug's advanced AI platform with PharmGen Science's developing gastrointestinal drugs, we aim to accelerate the development of differentiated innovative gastrointestinal drugs."
Hot Picks Today
"Suspicious Timing?"...Trump Traded Stocks After Praising Wartime Capabilities
- "I Went to 10 Convenience Stores and Still Couldn't Buy It": The Bread Sensation That Sold 100 Million Units Already [The Way We Shop Now]
- [Breaking] Trump: "U.S. and Nigerian forces eliminate IS number two"
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "Contact Me First If Houses Are Built": Wealthy Clients Eyeing... Will Ultra-High-End Residences Worth 20 Billion Won Be Developed? [Real Estate AtoZ]
Meanwhile, PharmGen Science declared its R&D vision this year with the goal of becoming the 'No.1 gastrointestinal new drug developer by 2030' and opened the 'Dongtan Campus Global Research Center' in Dongtan, Hwaseong-si, Gyeonggi Province on the 6th of this month, consolidating research facilities and personnel. Currently, it holds four new drug pipelines, and a liver contrast agent, for which domestic and international patents have been filed, has been selected as a national new drug development project. The new drug development roadmap includes two global license-outs by 2025, five gastrointestinal new drug pipelines by 2030, and the launch of one gastrointestinal new drug by 2032.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
